Eli Lilly (LLY) shares opened Friday’s session at $1,208.37, hovering close to the 52-week peak of $1,238.00. The pharmaceutical giant’s stock has climbed 14.4% since January, outperforming the pharma sector’s 11.6% advance and the broader S&P 500 index.
The Indianapolis-based drugmaker delivered first-quarter 2026 earnings of $8.55 per share, significantly surpassing Wall Street’s consensus forecast of $6.97. Total revenue reached $19.80 billion, beating projections of $17.82 billion and representing a 55.5% increase compared to the prior-year quarter.
The company’s dual GLP-1 blockbusters, Mounjaro and Zepbound, powered the majority of revenue expansion. These two medications alone contributed roughly 65% of all first-quarter sales. Following the U.S. market introduction of Foundayo — Lilly’s oral formulation for obesity treatment — analysts anticipate GLP-1 products will account for more than 65% of second-quarter revenue.
Foundayo’s arrival reignites direct market rivalry with Novo Nordisk (NVO), which introduced an oral Wegovy formulation in January 2026, securing a temporary first-mover advantage.
Lilly has accelerated efforts to broaden its product portfolio outside the obesity and diabetes segment. The pharmaceutical company is developing multiple therapeutic franchises designed to reduce dependence on GLP-1 revenue streams.
The diversification pipeline includes Omvoh for inflammatory bowel conditions, Jaypirca addressing specific blood malignancies, Ebglyss approved for atopic dermatitis treatment, Kisunla targeting early-stage Alzheimer’s disease, and Inluriyo recently launched for metastatic breast cancer.
Jaypirca has emerged as a standout performer. The FDA broadened its indication in late 2025 to include patients with relapsed or refractory CLL/SLL. Subsequently, Europe’s CHMP issued a positive recommendation for expanded approval covering all CLL treatment lines, with final European Commission authorization expected soon.
Lilly awaits a comparable FDA label expansion ruling for Jaypirca scheduled for later this year. Approval would substantially expand the addressable patient population across U.S. markets.
Regarding mergers and acquisitions, Lilly allocated more than $20 billion throughout 2026 toward deals encompassing oncology, neuroscience, cardiovascular therapeutics, gene editing platforms, and vaccine development. This represents a substantial commitment to long-range portfolio diversification.
At present trading levels, LLY shares command a forward earnings multiple of 30.67 — exceeding the pharmaceutical industry average of 18.76 while remaining below the company’s five-year historical mean of 34.56. Market capitalization currently stands at $1.14 trillion.
Full-year 2026 EPS projections have trended upward during the past 60 days, climbing from $33.86 to $35.67. Looking ahead to 2027, estimates advanced from $42.56 to $44.61.
Institutional investors control 82.53% of outstanding shares. World Investment Advisors expanded its position by 12.1% during the first quarter of 2026, purchasing 2,936 additional shares to reach a total holding of 27,134.
Wall Street analysts maintain predominantly bullish outlooks. Goldman Sachs assigns a buy rating with a $1,283 price objective. Jefferies recently elevated its target to $1,350, maintaining a buy recommendation. Morgan Stanley reaffirmed its overweight stance in June.
Among 30 analysts monitored by MarketBeat, 23 recommend buying the stock, with a median price target of $1,235.07.
The sole dissenting voice: HSBC downgraded shares to reduce in March, establishing an $850 price target.
Lilly’s official fiscal year 2026 guidance projects EPS between $35.50 and $37.00, while the current sell-side consensus estimate sits at $35.74.
The post Eli Lilly (LLY) Stock Surges Past $1,200 on Blockbuster Earnings and Oral GLP-1 Launch appeared first on Blockonomi.
